Robert Taylor Ripley, M.D.
Picture
Schedule an Appointment
Positions
- Associate Professor of Surgery
-
Division of Thoracic Surgery
Baylor College of Medicine
Houston, Texas United States
- Director, Mesothelioma Treatment Center
-
Baylor St. Luke’s Medical Center
Houston, Texas United States
- Co-Editor
-
Seminars in Thoracic and Cardiovascular Surgery
- Co-Director, Thoracic Oncology Working Group
-
Dan L Duncan Comprehensive Cancer Center
Houston, Texas United States
- Member
-
Baylor College of Medicine
Dan L Duncan Comprehensive Cancer Center
Houston, Texas United States
- Director of General Thoracic Surgery Research
-
Michael E. DeBakey Department of Surgery
Addresses
- Lung Institute (Clinic)
-
Baylor Medicine at McNair Campus
7200 Cambridge Street
Houston, TX 77030
United States
Phone: (713) 798-6376
lungsched@bcm.edu
- Sugar Land (Clinic)
-
1327 Lake Pointe Parkway
Suite 305
Sugar Land, TX 77478
United States
Phone: (713) 798-6376
Education
- Fellowship at Memorial Sloan-Kettering Cancer Center / New York Presbyterian-Weill Cornell Medical Center
- New York
- Residency at University of Colorado Denver
- Denver
- MD from Vanderbilt University School of Medicine
- Nashville
- BS from Boston College
- Chestnut Hill
- Biochemistry
- Fellowship at National Cancer Institute, NIH
- Bethesda
Certifications
- American Board of Surgery
- American Board of Thoracic Surgery
Honors & Awards
- 2016 NCI Director’s Innovation Award
- National Cancer Institute, NIH
- 2020 NCI Director’s Innovation Award
- National Cancer Institute, NIH
Professional Interests
- Mesothelioma
- Chest Wall Tumors and Reconstruction
- Lung Cancer
- Esophageal Cancer
- Thymoma and Thymic Carcinoma
- Robotic Thoracic Surgery
- Infectious Lung Diseases
- Pulmonary Metastases
- Thoracic Surgery
- Robotic Mediastinal Surgery
- Hiatal Hernias, Reflux, and Achalasia
Professional Statement
Dr. R. Taylor Ripley is the Director of the Mesothelioma Treatment Center. He is a nationally recognized, board-certified thoracic surgeon and expert in mesothelioma and thoracic surgical oncology. In addition to mesothelioma, he focuses on chest wall tumors, lung cancer, esophageal cancer, and thymoma / thymic carcinoma. For most tumors, Dr. Ripley specializes in robotic surgery to provide minimally invasive approaches to thoracic diseases. He also practices all facets of general thoracic surgery including infectious lung disease, benign esophageal diseases, and endoluminal interventions.Prior to joining the faculty at Baylor College of Medicine, Dr. Ripley was an Associate Professor of Surgery at National Cancer Institute, NIH. While at the NIH, Dr. Ripley was awarded the NCI Director’s Innovation Award for targeting specific p53-mutations for the treatment of esophageal adenocarcinoma. He established the Foregut Team at the NIH Clinical Center for the management of patients with esophageal cancer. He also started robotic thoracic surgery at the NCI, NIH. He established a laboratory in the metabolic reprogramming of thoracic cancer and has continued that work at Baylor College of Medicine.
Prior to his faculty appointment at the NCI, Dr. Ripley trained extensively in the care of patients with mesothelioma under world-renowned surgeons during his fellowship at Memorial Sloan-Kettering Cancer Center in New York. He also completed a fellowship in Surgical Oncology at the NCI, NIH. Dr. Ripley did general surgery residency at the University of Colorado and received his Medical Doctorate from Vanderbilt University.
Websites
Videos
Selected Publications
- R. Taylor Ripley "Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma." Thorac Surg Clin. 2020;
- R. Taylor Ripley, Caleb Euhus "The Staging of Malignant Pleural Mesothelioma." Thorac Surg Clin. 2020;
- R. Taylor Ripley, Paul H. Sugarbaker "Pleural and Peritoneal Mesothelioma." Oxford Textbook of Oncology. 2020;4th Edition
- Xu Y, Surman DR, Diggs L, et al. "Bile Acid-Induced ‘Minority MOMP’ Promotes Esophageal Carcinogenesis while Maintaining Apoptotic Resistance via Mcl-1." Oncogene. 2020 Jan;39(4):877-890. Pubmed PMID: 31570787
- Feingold PL, Surman DR, Brown K, et al. "Induction of ThioredoxinInteracting Protein by the Histone Deacetylase Inhibitor, Entinostat, Enhances Cisplatin-Mediated DNA Damage and Apoptosis in Esophageal Adenocarcinoma Cells." Mol Cancer Ther. 2018 Sep;17(9):2013-2023. Pubmed PMID: 29934340
- Yuan Xu, Paul L. Feingold, Deborah R. Surman, Kate Brown, Vivek Shukla, Sichuan Xi, Jeremy L, Davis, Jonathan Hernandez, David S. Schrump, R. Taylor Ripley "Bile Acid and Cigarette Smoke Enhance the Malignant Phenotype of Esophageal Adenocarcinoma by Downregulation of the Mitochondrial Membrane Protein, Uncoupling Protein-2." Oncotarget. 2017 Nov 10;8(60):101057-101071. Pubmed PMID: 29254145
- R. Taylor Ripley "Malignant Pleural and Pericardial Effusions." Principles and Practice of Oncology. 2019;
- Jeremy L. Davis, R. Taylor Ripley, Jonathan M. Hernandez "Endoscopic and Robotic Surgery." Principles and Practice of Oncology. 2019;
- R. Taylor Ripley, David R. Jones "Biology and Epidemiology of Lung Cancer." Pearson’s Thoracic and Esophageal Surgery. 2019;
- R. Taylor Ripley, M.D., Kei Suzuki, M.D., Kay See Tan, Ph.D., Prasad S. Adusumilli, M.D., James Huang, M.D., Bernard J. Park, M.D., Robert J. Downey, M.D., Nabil P. Rizk, M.D., M.S., Valerie W. Rusch, M.D., Manjit Bains, M.D., David R. Jones, M.D. "Postinduction PET assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer." J Thorac Cardiovasc Surg. 2016 Apr;151(4):969-979. Pubmed PMID: 26614420
- R. Taylor Ripley, Inderpal S. Sarkaria, Rachel Grosser, Camelia S. Sima, Manjit S. Bains, David R. Jones, Prasad S. Adusumilli, James Huang, David J. Finley , Valerie W. Rusch, Nabil P. Rizk "Pre-Treatment Dysphagia in Esophageal Cancer May Eliminate the Need for Staging by Endoscopic Ultrasonography.." Ann Thorac Surg. 2016 Jan;101(1):226-230. Pubmed PMID: 26603024
- R. Taylor Ripley, Robert R. McMillan, Camelia S. Sima, Saad M. Hasan, Usman Ahmad, Feiran Lou, David R. Jones, Valerie W. Rusch, Nabil P. Rizk, James Huang "Second Primary Lung Cancers: Smokers v. Non-smokers after Resection of Stage I Lung Adenocarcinoma.." Ann Thorac Surg. 2014 Sep;98(3):968-974. Pubmed PMID: 25038021
Memberships
- Journal of Thoracic and Cardiovascular Surgery
- Editorial Board Member
- Mesothelioma Applied Research Foundation
- Board of Directors
- American Association of Thoracic Surgery
- Member
- Association for Academic Surgeons
- Member
- International Association for the Study of Lung Cancer
- Member
- AATS Foundation
- Surgical Investigator Program
- Dan L Duncan Comprehensive Cancer Center
- Member
Log In to edit your profile
